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1. Introduction
The blood–brain–barrier (BBB) forms a 
highly selective barrier between the micro-
vascular blood stream and brain tissue; 
it is composed of endothelial cells (ECs), 
which form the microvasculature, sur-
rounded by pericytes and astrocytes,[1,2] 
and regulates the passage of substances 
between the blood and brain, maintaining 
brain homeostasis, while providing a bar-
rier against pathogens and neurotoxins.[2] 
Due to its high selectivity, the BBB also 
represents a major obstacle to the efficient 
delivery of large molecules for the treat-
ment of brain diseases.[3–5]
Polymer nanoparticles (NPs), by virtue 
of their small size and tunable properties, 
have been explored for delivering diag-
nostic agents,[6] nucleic acids,[7,8] proteins,[9] 
and traditional small molecule medicines 
to the brain.[10] Specifically, their chemical 
properties can be tuned to achieve target 
stability, drug encapsulation, and release 
Polymer nanoparticles (NPs), due to their small size and surface functionalization 
potential have demonstrated effective drug transport across the blood–brain–bar-
rier (BBB). Currently, the lack of in vitro BBB models that closely recapitulate 
complex human brain microenvironments contributes to high failure rates of neu-
ropharmaceutical clinical trials. In this work, a previously established microfluidic 
3D in vitro human BBB model, formed by the self-assembly of human-induced 
pluripotent stem cell-derived endothelial cells, primary brain pericytes, and astro-
cytes in triculture within a 3D fibrin hydrogel is exploited to quantify polymer NP 
permeability, as a function of size and surface chemistry. Microvasculature are 
perfused with commercially available 100–400 nm fluorescent polystyrene (PS) 
NPs, and newly synthesized 100 nm rhodamine-labeled polyurethane (PU) NPs. 
Confocal images are taken at different timepoints and computationally analyzed to 
quantify fluorescence intensity inside/outside the microvasculature, to determine 
NP spatial distribution and permeability in 3D. Results show similar permeability 
of PS and PU NPs, which increases after surface-functionalization with brain-
associated ligand holo-transferrin. Compared to conventional transwell models, 
the method enables rapid analysis of NP permeability in a physiologically relevant 
human BBB set-up. Therefore, this work demonstrates a new methodology to 
preclinically assess NP ability to cross the human BBB.
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properties.[11] The passage of NPs through the BBB seems to 
be mostly size-dependent. For instance, particles with 10 to 
< 1000 nm size have been commonly used for drug delivery to 
the brain,[11,12] and particularly, 100 nm NPs have demonstrated 
favorable delivery capabilities.[13–16]
Additionally, it has been shown that surface modification of 
NPs with ligands for specific binding to BBB cells enhances 
NP accumulation in the brain through receptor-mediated 
endocytosis.[17–20] Among these,[21,22] holo-transferrin (Tf) has 
been widely studied as it binds to the Tf receptor (TfR), which 
is more abundantly expressed by brain ECs compared to ECs 
of other blood vessels,[21,23] and overexpressed by brain tumor 
vasculature.[12,24,25] Notably, TfR-targeting NPs have been found 
to improve drug delivery into brain tissue.[22,26–28] Despite evi-
dence suggesting that NPs with specific size and surface com-
position can accumulate in the brain, the clinical translation of 
such approaches has not been achieved successfully.
Currently, in vivo xenograft mouse models are used for 
the preclinical evaluation of NP efficacy.[29] However, crucial 
cellular, genetic, immunologic, and molecular differences exist 
between humans and mice, limiting the capability of animal 
models to screen for therapeutics that effectively target the 
human brain.[30,31] Animal models also raise ethical issues, are 
costly and time-consuming.[32] As such, more human-relevant 
and efficient platforms are needed.
Microfluidic or “organ-on-a-chip” models have the potential 
to accelerate the in vitro preclinical evaluation and screening 
of NPs for effective therapies.[33–36] Among the many 2D and 
3D vascular models, only few 3D in vitro models of func-
tional brain vasculature have been described.[37–39] However, 
they typically show larger diameters (600–800 µm) compared 
to brain vessels (arterioles and venules: 1–100 µm; capillaries: 
5–10 µm), which results in altered transport properties. To 
address such limitations, a 3D in vitro microfluidic model of 
the human BBB microvasculature has been recently developed 
by the authors, by the triculture of human induced pluri-
potent stem cell-derived ECs (iPSC-ECs), primary human 
pericytes, and astrocytes in 3D fibrin hydrogel (Figure 1; 
Adv. Healthcare Mater. 2020, 9, 1901486
Figure 1. a) Schematic representation of the BBB and b) vascular cross-section. c) Illustrative description of culture protocol, from 2D culture of 
each cell type to generation of a 3D in vitro human BBB in a matrix environment within a microfluidic system. The microfluidic system was fabricated 
using PDMS by soft lithography techniques and was designed with gel inlet ports for injecting fibrin gel, and media reservoirs for injecting cell cul-
ture medium. d) Timeline of experimental protocol with the associated growth and morphology of BBB microvasculature over time in the 3D in vitro 
microfluidic system. All schematics were created with BioRender.
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Figures S1 and S2, Supporting Information).[37] Here, cocul-
tured cells self-assembled into complex structures, recapitu-
lating brain vascular morphogenesis; during the 7 days culture, 
iPSC-ECs increased their expression of tight junction proteins, 
including Zonula occludens-1 (ZO-1), Occludin (OCLN) and 
Claudin-5 (CLDN5), and common brain EC membrane trans-
porters.[37] The model exhibited many features that mimic the 
human BBB, and showed similar vascular permeability to rat 
brain microvasculature (Figure S1, Supporting Information).[37]
In this work, we applied this physiologically relevant tool 
to evaluate NP transport across the BBB. To achieve this, a 
method was proposed for studying in vitro transport of fluo-
rescently tagged polymer NPs in the 3D model. The effects of 
NP size and Tf surface functionalization (Figure 2a) on perme-
ability values were studied, using two types of polymer NPs: 
commercially available polystyrene (PS) and newly synthesized 
polyurethane (PU) NPs. The 3D model allowed for more rapid 
evaluation of NP permeability than using a 2D transwell set-up 
(5 min versus 3 h) and could effectively capture the effect of 
NP surface functionalization. Therefore, the work represents 
a proof of concept that advanced in vitro 3D BBB models can 
potentially predict NP transport to the brain and are useful for 
preclinical screening of nanotherapeutics.
2. Results
2.1. RT-qPCR of Surface and Junction Protein Expression 
by Endothelial Cells (ECs)
Preliminary experiments were aimed at supporting the use of 
iPSC-ECs in the BBB microvasculature model, and at selecting 
a proper functionalizing ligand for NPs. Different EC types 
(human brain microvascular EC; HBMECs, iPSC-ECs and, as 
control cells, human umbilical vein ECs; HUVECs) were cul-
tured in vitro for 7 days on tissue culture plates.
Results for HUVECs showed that the TfR was one of the most 
highly upregulated amongst other brain-specific transporters, 
including large neutral amino acid transporter 1 (LAT1) and 
multidrug resistance-associated protein 4 (MRP4) (Figure 2b). 
The TfR was also one of the most highly upregulated surface pro-
teins on iPSC-ECs (2.91-fold expression compared to HUVECs) 
(Figure 2b). HBMECs upregulated several surface and junction 
proteins of tight intercellular junctions and showed high expres-
sion of multiple brain-specific transporters (Figure 2b). Addition-
ally, HBMECs have been previously observed to self-assemble 
into large and discontinuous microvascular networks, while 
iPSC-ECs form a complex and perfusable microvasculature 
when cultured in a 3D matrix.[37] Based on these results, iPSC-
ECs were selected for the development of a functional 3D in vitro 
BBB microvasculature model to test Tf-functionalized NPs.
2.2. Physical Characterization of PS and PU NPs with/without 
Tf-functionalization
The PU NPs used in this study are spherical in shape, as shown 
by transmission electron cryomicroscopy (Cryo TEM) images 
(Figure S3, Supporting Information) and previous studies.[40] 
Similarly, commercial PS NPs possess a spherical shape.[41] Com-
mercially available PS NPs and synthesized PU NPs were used 
and surface-functionalized with Tf, following published methods, 
exploiting carbodiimide-mediated grafting (Figure 2a).[42] PS and 
PU NPs displayed a narrow size distribution (Figure 2c), but after 
Tf-functionalization, they increased their size and zeta potential 
(Figure 2c and Table 1), in agreement with previous literature.[40,42]
2.3. Cytocompatibility and Cell Uptake of PS and PU NPs
MTS cell viability assays confirmed that NPs were not cyto-
toxic for iPSC-ECs at the concentrations tested (0–500 µg mL−1, 
showing: 81.7% ± 5.8% viability compared to the non-treated 
control (Figure 2d). Additionally, analysis of 3D confocal images 
of iPSC-ECs incubated in the presence of NPs (Figure 2e) con-
firmed that the cells internalized NPs (Figure 2f,g), which suc-
cessfully localized in the region close to cell nuclei (Figure 2h).
2.4. PS and PU NP Permeability across a 2D Monolayer in a 
Transwell Model
A 2D transwell model of the BBB was set up (Figure 2i), 
showing an increase in trans-endothelial electrical resist-
ance (TEER) values, as a function of culture time from 
130.0 ± 8.3 Ω cm2 after 24 h, to 189.0 ± 3.4 Ω cm2 after 2–3 days 
(Figure 2j). The 2D transwell model was used to measure NP 
permeability: PS NPs with 100–400 nm size showed similar 
permeability (Figure 2k), while PU NPs showed significantly 
higher permeability compared to PS NPs (Figure S4, Sup-
porting Information). Permeability of PS-Tf NPs showed a 2.06-
fold significant increase compared to non-functionalized PS 
NPs after 3 h (Figure 2k). By contrast, permeability of PU-Tf 
NPs was not significantly higher than that of PU NPs after 
1 and 3 h testing time (Figure 2l). Additionally, the permeability 
of both FITC-dextran and NPs did not change when they were 
tested in combination (Figure S5, Supporting Information).
2.5. PS and PU NP Permeability across a 3D Microvasculature 
in a Microfluidic Model
The 3D in vitro BBB model (Figure 1, Figure 3a,b; Figures S1 
and S2, Supporting Information) was utilized for permeability 
measurements. Permeability of FITC-dextran decreased with 
an increase in its molecular weight (10 kDa: (2.21 ± 1.96) × 
107 cm s−1; 40 kDa: (0.83 ± 0.86) × 107 cm s−1; 70 kDa: 
(0.62 ± 0.39) × 107 cm s−1) (Figure 3c), in agreement with 
previous literature.[37] Permeability values of PS NPs with dif-
ferent size did not change significantly (100 nm: (1.64 ± 1.36) × 
107 cm s−1; 200 nm: (1.33 ± 0.87) × 107 cm s−1; 400 nm: 
(1.42 ± 0.72) × 107 cm s−1) (Figure 3d), while it significantly 
increased for PS-Tf NPs (3.09 ± 3.26) × 107 cm s−1) over non-
Tf-functionalized NPs (Figure 3e). PU NPs showed similar 
permeability ((1.58 ± 1.16) × 107 cm s−1) as PS NPs, which sig-
nificantly increased for PU-Tf NPs ((3.70 ± 2.72) × 107 cm s−1) 
(Figure 3f). The permeability of FITC-dextran did not change in 
the copresence of NPs (data not shown).
Adv. Healthcare Mater. 2020, 9, 1901486
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Figure 2. a) Method of preparing Tf-functionalized PU NPs (left) and TfR-mediated endocytosis of Tf-functionalized NPs (right). Image created 
with BioRender. b) Relative RT-qPCR of surface and junction proteins by different ECs cultured over 7 days in 2D. A comparison is shown of mRNA 
expression of factors relating to brain endothelial transporter proteins, regulation of microvasculature maturation and BBB features. Fold change is 
relative to control HUVEC monoculture, with GAPDH as the internal standard housekeeping gene. c) Size distribution curves of NPs with/without Tf 
www.advancedsciencenews.com www.advhealthmat.de
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2.6. 3D Spatiotemporal Distribution of PS and PU NPs across 
the 3D Microvasculature
3D confocal images of the microvasculature perfused with NPs 
allowed quantification of spatial and time-dependent distribu-
tion of NPs (Figure 4a). There was a mean 2.5-fold increase 
in fluorescence intensity in the region close to the narrowest 
vessel lumen over two subsequent timepoints (Figure 4b). 
Slight changes in fluorescence intensity could be detected as far 
as 100 µm distance from the vessel wall (Figure 4c,d).
3. Discussion
This study proposed a new method to characterize polymer 
NP transport across a previously developed human BBB 3D 
in vitro model (Figure 1; Figures S1 and S2, Supporting Infor-
mation).[37] In previous work, we found that both pericytes 
and astrocytes (ACs) contribute toward improved BBB forma-
tion, structural integrity, relative gene expressions, as well as 
microvessel morphology, diameter, and microvascular permea-
bility.[37] We also observed an increase in tightness of junctional 
proteins that was consistent with the progressive reduction 
of microvascular permeability in the triculture BBB model.[37] 
Based on previous permeability results, we expect higher NP 
microvascular permeability in the conditions of iPSC-EC mono-
culture and coculture with ACs. Further investigations would 
ascertain the relative importance of the different cellular com-
ponents of the BBB on the transport of nanocarriers into the 
central nervous system.
In this study, we first performed relative RT-qPCR analysis 
on 2D monocultures of iPSC-ECs, HBMECs and HUVECs to 
validate the use of iPSC-ECs in the model and to select a proper 
ligand for NP surface functionalization. HUVECs were used 
as control cells as they are not specific for the brain microvas-
culature and can recapitulate the function of generic vascular 
ECs.[43,44] Results showed that the TfR was one of the most 
highly upregulated surface proteins on iPSC-ECs compared 
to HUVECs (Figure 2b and Table S1, Supporting Informa-
tion). TfR expression is expected to be further upregulated in 
the 3D in vitro human BBB model, which comprises iPSC-
ECs, human pericytes, and astrocytes (Figure 1). Pericytes and 
astrocytes secrete brain-specific growth factors, which support 
the formation of the tight intercellular junctions that give rise 
to low BBB permeability.[45,46] Moreover, the presence of tight 
junctions in the previously developed 3D in vitro human BBB 
model suggests that a paracrine effect is exerted by astrocytes 
and pericytes on iPSC-ECs, which would hence increase TfR 
expression.[37]
HBMECs showed significantly higher expression levels of 
the TfR and other brain-specific transporters, such as LAT1 and 
monocarboxylate transporter-1 (MCT1), compared to HUVECs 
(Figure 2b). However, HBMECs were previously observed to 
self-assemble into large and discontinuous microvascular net-
works, which makes them unsuitable for developing a func-
tional BBB microvasculature model.[37] On the other hand, 
iPSC-ECs were demonstrated to form a complex and perfusable 
microvasculature when cultured in a 3D matrix.[37] Addition-
ally, iPSC-ECs are an easily available cell source and may allow 
for patient-personalized research.[30] Based on these results, 
iPSC-ECs were appropriate for generating the 3D in vitro BBB 
model, while the TfR was selected as a proper target receptor in 
the study of NPs in this model. Indeed scientific literature has 
previously highlighted the therapeutic potential of Tf-based NP 
transport across the BBB.[22,26–28] Tf can also be expressed by 
brain microcapillaries and other ECs[47] such as those of liver 
capillaries and might play an important role for NP transport 
across liver-specific microvessels. Further studies can involve 
the surface-functionalization of NPs with other brain-specific 
ligands, which can further validate and optimize the BBB 
model for preclinical screening of nanotherapeutics.
In this study, PS and PU NPs with narrow size distribution 
were used (Figure 2c). After Tf-functionalization, PS-Tf NP size 
and zeta potential increased (Table 1), in agreement with pre-
vious studies that performed complete physicochemical charac-
terizations of such NPs.[42] By contrast, the size of PU-Tf NPs 
did not change significantly compared to PU NPs, and there 
was a slight, but statistically significant increase in zeta poten-
tial. These differences in size and zeta potential of NPs after Tf 
grafting could be attributed to the different initial surface com-
position of PS versus PU NPs, which would affect the confor-
mation and amount of grafted Tf molecules.
Cell viability assays confirmed that NPs were not cytotoxic 
for up to 10× the concentration used in permeability studies 
(Figure 2d). Confocal microscopy analysis also showed that 
iPSC-ECs internalized NPs (Figure 2e–g), which then localized 
Adv. Healthcare Mater. 2020, 9, 1901486
Table 1. DLS characterization of PS and PU NPs.
NP type Size [nm] PDI ZP [mV]
100 nm (PS) 109.0 ± 0.8 0.0377 ± 0.02 −43.7 ± 0.3
200 nm (PS) 233.0 ± 0.6 0.0373 ± 0.03 −37.0 ± 2.4
400 nm (PS) 457.0 ± 16.5 0.122 ± 0.07 −37.4 ± 2.0
100 nm (PS-Tf) 203.0 ± 3.1 0.215 ± 0.04 −0.04 ± 0.2
PU 112.0 ± 1.0 0.0940 ± 0.01 −44.9 ± 4.0
PU-Tf 118.0 ± 1.4 0.157 ± 0.01 −32.2 ± 0.5
as characterized by DLS measurements. d) Nonsignificant difference in iPSC-EC viability toward increasing NP concentrations, with results presented 
as the percentage compared to the untreated control (0 µg mL−1 NPs). e) Method for quantifying cell uptake and nuclei localization of NPs. Confocal 
images showing cell uptake of f) PS NPs with/without Tf and g) PU NPs. h) Percentage of NPs localized at nuclei compared to total NPs per cell. 
i) Transwell set-up to evaluate NP transport across an iPSC-EC monolayer, which was assessed by the ratio of measured fluorescence intensity of media 
collected from the bottom and top of the transwell insert. j) TEER characterization of iPSC-EC monolayer indicates cell confluence and presence of 
tight intercellular junctions. Fold change in net movement of NPs across an iPSC-EC monolayer in the transwell set-up from 0 h for k) PS and l) PU 
NPs. Data were analyzed using a two-tailed Student’s t-test and where appropriate, one-way ANOVA with Holm–Sidak’s multiple comparisons test 
or Kruskal–Wallis H test with Dunn’s multiple comparisons test. Data are shown as the mean ± SD, n ≥ 3 independent experiments, with * p ≤ 0.05. 
(n.s.: not significant)
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Figure 3. a) Set-up and method of 3D permeability measurements. Representative confocal images of NPs, which fluoresce in the red fluorescence 
channel, transporting across the microvasculature are shown. b) Approach for measuring intensity of NPs within/outside microvasculature at different 
timepoints for 3D permeability analysis. 3D permeability measurements of c) FITC-dextran, d) bare PS NPs, e) bare PS NPs and PS-Tf NPs, and f) bare 
PU and PU-Tf NPs in 3D. Data were analyzed using a two-tailed Student’s t-test and where appropriate, one-way ANOVA with Holm–Sidak’s multiple 
comparisons. Data are shown as the mean ± SD, n ≥ 3 independent experiments, with * p ≤ 0.05, *** p ≤ 0.001, p ≤ 0.0001. (n.s.: not significant).
www.advancedsciencenews.com www.advhealthmat.de
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near the cell nuclei (Figure 2h). This result suggested that NPs 
could possibly cross the BBB model via transcytosis, as NPs 
could be packaged into vesicles near the nuclei to then be traf-
ficked out of the cell.[48,49]
A 2D transwell model was set up to measure NP trans-
port across an iPSC-EC monolayer (Figure 2i). Its increase 
in TEER values over time suggested the formation of tight 
intercellular junctions (Figure 2j). NPs were able to cross 
such monolayers, and no substantial difference in the 
permeability of PS NPs with different sizes were observed 
(Figure 2k), in agreement with literature.[50] At least 3 h were 
needed to detect an increase in permeability for PS-Tf NPs 
compared to PS NPs (Figure 2k), while the permeability of 
PU and PU-Tf NPs was similar after 1 and 3 h testing time 
(Figure 2l). Hence, in addition to their lack of 3D architec-
tural complexity, 2D transwell assays do not facilitate direct 
comparisons across NPs made of different materials and are 
time-consuming.
Adv. Healthcare Mater. 2020, 9, 1901486
Figure 4. a) 3D intensity map showing localization and density of NPs outside microvasculature over time. b) Fold change in signal intensity of 
fluorescent dextran (FITC) and NPs (red fluorescence) over two timepoints. c) Confocal images showing sections being sampled using line scan 
measurements (yellow line) at different timepoints to generate the d) intensity profile histogram of the fluorescence signal of NPs at two timepoints 
along the line indicated in (c).
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By contrast, the 3D in vitro BBB model allowed for per-
meability comparisons across NPs prepared using different 
materials or with Tf surface functionalization, in a short time 
(5 min) (Figure 3a,b). Permeability values of non-functionalized 
PS NPs measured in the 3D model did not change as a func-
tion of NP size in the 100–400 nm range (Figure 3d).
Although the surface chemistry of PS and PU NPs was dif-
ferent, non-functionalized PU and PS NPs showed similar 
permeability values. Notably, the permeability of non-function-
alized NPs in the 3D model was twofold higher than for 40 and 
70 kDa FITC-dextrans (Figure 3c,d). By contrast, NP perme-
ability across the 2D transwell monolayer was inferior to that of 
70 kDa FITC-dextran (Figure S5, Supporting Information). Pre-
vious authors also reported one order of magnitude lower per-
meability values in a 3D model compared with a 2D transwell 
model.[51] In the 3D in vitro model, transcytosis possibly played 
a more important role compared to paracellular transport. Con-
versely, in the 2D transwell set-up, transcytosis effects were 
possibly inferior and paracellular transport prevailed. Also, 
transcytosis mechanisms may possibly differ between in vitro 
2D monolayers and 3D environments.[52] Receptor-mediated 
transport can additionally differ for an EC monoculture (tran-
swell set-up) versus a system where ECs receive supporting 
factors from pericytes and astrocytes and thus display tighter 
intercellular junctions (3D BBB model).[53,54] Furthermore, NP 
and FITC-dextran permeabilities did not change when they 
were tested in combination in 2D (Figure S5, Supporting Infor-
mation); similarly, FITC-dextran permeabilities did not change 
in 3D models (data not shown). This suggested that NPs did not 
alter the tightness of cell junctions. Future studies can further 
explore the primary mechanisms responsible for NP transport.
Tf-functionalization increased permeability values espe-
cially for PU-Tf NPs (Figure 3f). Such results are particularly 
relevant for future translation of PU NPs to the clinic, consid-
ering their demonstrated efficient delivery of drugs to tumors 
in murine models.[40] In the case of PS-Tf NPs, the method for 
Tf surface grafting has been previously demonstrated to cause 
partial protein denaturation, decreasing Tf binding interaction 
with iPSC-ECs.[20,55] Additionally, NP permeability in the pres-
ence of culture medium can be affected by the formation of a 
protein corona around NPs.[56,57] On the other hand, PU NPs 
were functionalized using a PEGylated Tf: the PEG segment 
functioned as a spacer, providing Tf flexibility and exposure,[58] 
and as an anti-fouling agent, reducing nonspecific protein 
adsorption,[59] and preserving Tf biological function. Hence, 
PU-Tf NPs presented Tf more effectively to TfRs on iPSC-ECs, 
possibly resulting in improved transcytosis.[60] Additionally, the 
surface of PU-Tf NPs also contained lipid molecules that may 
increase NP affinity for cells.[40] Future studies that quantify the 
amount of biologically active Tf on the NP surface would con-
firm such hypotheses.
An algorithm was developed to spatially detect precise fluc-
tuations in fluorescence signals of FITC-dextran and NPs. By 
analyzing NP distribution in 3D space within and outside the 
microvasculature (Figure 4a), a mean 2.5-fold increase in flu-
orescence intensity was quantified in the region close to the 
narrowest lumen over two subsequent timepoints (Figure 4b). 
Changes in fluorescence intensity could be detected as far 
as 100 µm distance from the vessel wall (Figure 4c,d). In 
vivo, neurons are ≈10 to 20 µm from the brain capillaries,[61] 
implying that in a hypothetical in vitro BBB model incorpo-
rating neurons,[62] NPs can travel across the BBB and reach the 
target neurons.
In our study, certain regions of the BBB microvasculature 
appeared to be leaky. This was possibly due to the heteroge-
neous expression of tight junctions and incomplete matura-
tion of the microvasculature, resulting in a local increase in NP 
permeability. A possible method of reducing vessel leakiness is 
to continuously perfuse vessels with fluid flow which has been 
demonstrated to improve microvascular formation. Flow-medi-
ated shear stress is known to promote the differentiation of vas-
cular ECs toward a more BBB-like phenotype and increase their 
expression of tight junction proteins and membrane trans-
porters, further reducing vessel permeability.[63]
The data provided here present a new application of a pre-
viously developed 3D in vitro human BBB microvasculature 
model and an effective and convenient methodology for quan-
tifying the transport and distribution properties of NPs across 
the model. Notably, model reproducibility depends on consist-
ency of experimental parameters, including device geometry, 
and the specific batch and passage number of each cell type. 
Overall, our findings contribute insight on the influence of NP 
size, composition and surface functionalization on their trans-
port properties.
In the future, the same methodology could be applied to a 
diseased BBB model, obtained by culturing the cells in the pres-
ence of inflammatory cytokines.[64] Indeed, a leakier BBB has 
often been associated with brain pathologies such as Parkin-
son’s disease, stroke,[65,66] and cancer metastasis to the brain.[67]
Moreover, the BBB model could be grown using iPSCs 
derived from patients with specific neurodegenerative diseases 
and unique genetic profiles, thereby producing a patient-spe-
cific pathological model to screen the efficacy and transport of 
nanocarriers for patient subgroups. Personalized drug design 
could thus be tailored to the patient based on the screening 
results of the patient-specific BBB model. It remains unclear 
if there is significant variation in the BBB between patients 
and if there are significant differences in the results obtained 
using personalized in vitro models versus generic cell lines. 
However, the use of iPSC-ECs for developing patient-specific 
in vitro models can encourage further investigations that clarify 
these differences.[68] Therefore, the here-proposed methodology 
could contribute toward a better understanding of disease-
specific transport processes and signaling molecular pathways, 
potentially leading to the discovery of new targets and candi-
date membrane transporters to enable improved drug delivery 
across the BBB.
4. Conclusion
This work reports initial findings on the application of a pre-
viously characterized self-assembled 3D in vitro human BBB 
model, for the evaluation of the transport and spatiotemporal 
distribution of different polymer NPs. The proposed method-
ology utilized fluorescently tagged NPs and was able to cap-
ture the boost in transport of Tf-functionalized NPs in a few 
minutes. Results are highly relevant from the perspective of 
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nanotherapeutic preclinical screening according to the prin-
ciple of the 3Rs (reduction, refinement, replacement).[69] In 
the future, this 3D in vitro platform could potentially enable 
patient-specific evaluation of drug-loaded NP delivery to the 
brain.
5. Experimental Section
Materials: For seeding of microfluidic devices: polydimethylsiloxane 
(PDMS) (Sylgard 184 silicone elastomer kit) was purchased from Dow 
Corning. Fibrinogen (cat. no. F8630), fibronectin (cat. no. C010), poly-
l-lysine (cat. no P4707), and thrombin (cat. no. T9549) were purchased 
from Sigma-Aldrich.
For PU synthesis: poly(ε-caprolactone)-diol (PCL-diol (2000 g mol−1), 
poly(ethylenglicole) (PEG 2000 g mol−1), n-BOC serinol, dibutyl 
dilaurate, and 1,6 hexamethylene diisocyanate were purchased from 
Sigma-Aldrich (Milan, Italy).
For PU NP preparation: l-α-phosphatidylglycerol (Egg-PG), 
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[carboxyl(polyethylene 
glycol)-2000] (DSPE-PEG-COOH), and l-α-phosphatidylethanolamine-
N-(lissamine-rhodamine B-sulfonyl) (Egg-Liss-Rhod PE) were purchased 
from Avanti Polar Lipids (Alabaster, AL, USA). Holo-Tf Human (cat. no. 
T4132), N-(3-dimethylaminopropyl)-N·-ethylcarbodiimide hydrochloride 
(EDC), N-hydroxysuccinimide (NHS), and 2-(N-morpholino)
ethanesulfonic acid (MES) hemisodium salt, were purchased from Sigma-
Aldrich (Milan, Italy).
Red fluorescent carboxylate PS NPs (cat. no. F8801, F8810, 
FluoSpheres) were purchased from Life Technologies and Spherotech 
(cat no. CFP-0562-2).
Preparation and Characterization of NPs: PS NPs (100, 200, 
400 nm) were covalently conjugated with human holo-Tf as previously 
described.[42] Bare carboxylic-modified 100 nm PS NPs (2.2 mg mL−1) 
were incubated with Tf (2.2 mg mL−1) in MES buffer (50 × 10−3 m) for 
2 h at room temperature (RT). Tf-conjugated NPs were collected by 
centrifugation, suspended in Milli-Q water and stored at 4 °C for further 
use.
PU NPs were prepared by the nanoprecipitation method as previously 
described.[40] Briefly, the polymer was dissolved in acetonitrile and 
dropped into a water solution of lipids, containing Egg-PG (200 µg), 
DSPE-PEG-COOH (240 µg), and Egg-Liss-Rhod PE (5 µL). The particle 
suspension was centrifuged at 3200 rpm. For Tf covalent coupling, 
NPs were collected, resuspended in MES buffer, containing EDC and 
NHS (1:2.5 molar ratio) and incubated for 30 min at RT to activate the 
carboxyl groups on the surface. Activated NPs were quickly collected by 
centrifugation, resuspended in Dulbecco’s phosphate buffered saline 
(DPBS) containing Tf (1:16 molar ratio to COOH), and incubated at 4 °C 
overnight. Tf-conjugated NPs were then collected, suspended in Milli-Q 
water and stored at 4 °C for further use.[40,42]
DLS and zeta-potential analysis were conducted using a Malvern 
ZS90 zeta-sizer (Nano ZS, Malvern, UK) to respectively measure the 
hydrodynamic diameter, polydispersity, and zeta potential of different 
NPs. Cryo TEM was performed by dropping a PU NP suspension (7 µL, 
0.5 mg mL−1) onto a carbon-coated copper mesh grid.
Cell Culture: Human iPSC-ECs (Cellular Dynamics International, CDI) 
and HBMECs (Angio-proteomie, cAP-0002) were cultured on flasks 
coated with human fibronectin (Millipore) (30 µg mL−1) in vascular 
endothelial growth factor (VEGF) (VascuLife VEGF Medium Complete 
Kit, Lifeline with iCell media supplement, CDI). Human primary 
astrocytes and pericytes (ScienCell) were cultured on flasks coated 
with poly-l-lysine in culture medium (ScienCell), and maintained in a 
humidified incubator (37 °C, 5% CO2). HUVECs (Lonza, C2519AS) were 
cultured in EGM-2 media (Endothelial Cell Growth Medium-2 Bulletkit, 
Lonza). Culture medium was replaced every 2 days and cells were used 
between P3 to P5.
Real-Time RT-qPCR: To measure protein expression of junction and 
transporter proteins, total RNA was isolated from iPSC-ECs, HBMECs 
and HUVECs after 7-days culture in 2D tissue culture plates by RNeasy 
Mini kit (Qiagen). Reverse transcription was performed using a 
SuperScript VILO cDNA Synthesis Kit (Invitrogen, Waltham, MA, USA) 
to synthesize cDNA from mRNA. The primer sequences are shown in 
Table S1, Supporting Information. Real-time RT-PCR was performed 
with a 7900HT Fast Real-Time PCR System (Applied Biosystems) using 
SYBR Premix Ex Taq II (Takara). The mRNA level of glyceraldehyde 
3-phosphate dehydrogenase (GAPDH; housekeeping gene) was set 
to 100% and used as the internal standard in all experiments. RT-PCR 
experiments were repeated at least three times for cDNA prepared from 
at least three batches.
MTS Assay: iPSC-ECs were seeded in 96-well plates and allowed to 
grow to confluency (≈80%). NPs were resuspended using different 
concentrations (0–500 µg mL−1 in culture medium), added to cells 
and left in the incubator for up to 4 h. Thereafter, cells were rinsed 
twice with DPBS before adding fresh medium without NPs but with 
the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) reagent. The MTS assay was then 
performed following the manufacturer’s instructions (CellTiter 96 
AQueous One Solution Cell Proliferation Assay, Promega). Absorbance 
measurements were performed using the VMax microplate reader 
(Molecular Devices).
Imaging and Quantification of Cellular NP Uptake: iPSC-ECs were 
plated on glass-bottom dishes (Matek, cat no. P35G-0-14-C) and allowed 
to grow to confluency (≈80%). To visualize cells, cells were stained with 
Cell Tracker Green (CMFDA; 2 × 10−6 m) following the manufacturer’s 
instructions. NPs (50 µg mL−1 in culture medium) were added to the 
labeled cells and then incubated for up to 4 h. After 4 h, cells were 
rinsed twice with DPBS to remove excess NPs before fixation with 
4% paraformaldehyde and counterstained with DAPI (1:1000). Cells 
were imaged using confocal microscopy (1024 × 1024 pixels, 60× 
magnification) for at least three different regions of interest (ROI).
NP uptake was quantified by measuring the fluorescence intensity of 
the NP within two different 3D regions: i) a region close to the nuclei 
(includes the nucleus and a 1 µm thick layer surrounding the nucleus) 
and ii) the cytoplasm. These were generated using Fiji software by 
applying the Trainable Weka Segmentation plugin and previously trained 
classifiers. The NP signal was first processed to remove background 
signal by using the filter “Remove Background” with a rolling radius 
of 15 pixels. The amount of fluorescence signal (a.u.) was determined 
in each region by multiplying the volume of the respective region and 
the volume-averaged value of the signal. Then, a ratio was obtained by 
dividing data of the nuclei-associated region by the signal within the 
cytoplasmic region.
Transwell Set-Up: iPSC-ECs were seeded in transwell inserts (1 µm 
pore size; Corning) and allowed to grow to confluency over 2–3 days. 
Cell confluency, hence functionality of tight intercellular junctions, 
was assessed by measuring TEER using EVOM2 (World precision 
instrument) with silver/silver-chloride chopstick electrodes (STX2) 
between the cell-seeded insert and bottom surface of the culture plate 
well where the TEER probe was fully submerged in culture medium 
during measurement.
In a first set of experiments, after the formation of a confluent 
iPSC-EC monolayer, culture medium was aspirated, and cells were 
incubated (1 and 3 h) with the NP suspension (200 µL, 50 µg mL−1 in 
culture medium) in the transwell insert, while culture medium (200 µL) 
was added in the bottom well. At each timepoint, medium in the insert 
and well was separately collected. The total fluorescence signal of each 
medium sample was measured by VMax micro plate reader (molecular 
devices). NP transport across the iPSC-EC monolayer was assessed by 
the ratio of measured fluorescence intensity of media collected from the 
bottom and top of the transwell insert (Figure 2i).
In a second set of experiments, a solution of only 70 kDa FITC-
dextran (100 µg mL−1 in DPBS) or containing both FITC-dextran and NPs 
(100 µg mL−1 FITC-dextran, and 50 µg mL−1 NPs in DPBS) was prepared. 
After formation of a confluent iPSC-EC monolayer, culture medium was 
aspirated, and cells were incubated with the FITC-dextran solution with/
without NPs (200 µL) in the transwell insert, while DPBS (200 µL) was 
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added in the bottom well. 3D z-stack images of the region above and 
below the insert membrane (interspace: 500 µm) were captured using 
a confocal microscope (800 × 800 pixels, 20× magnification) after 0 and 
5 min. Then, permeability across the 2D monolayer was quantified using 
Fiji software by considering the fluorescence intensities at both regions 
at 0 min (Itop0 and Ibottom0) and at 5 min (Itop5 and Ibottom5) for the green 
(FITC-dextran) and red (NPs) fluorescence channels, using Equation (1)
Permeability =
-
bottom5 bottom0 b
T top5 top0
I I V
A t I I( )
( )−
∆
 
(1)
where the subscript I is the mean intensity of the signal within the ROI, 
Vb is the volume of bottom solution in the observation area, AT is the 
lateral surface of the transwell membrane (3.2 mm × 3.2 mm), and ∆t = 
t2–t1 is the duration of the test (5 min).
Development of 3D In Vitro Human BBB Microvasculature: The 
3D BBB microvasculature was established following a previously 
reported protocol (Figure 1).[37] First, microfluidic devices, designed 
using AutoCAD (Autodesk) (height: 150 µm, fluidic channel width: 
1340 µm, main channel width: 2200 µm, distance between posts: 
150 µm; Figure S2, Supporting Information), were fabricated using soft 
lithography methods as previously described.[36]
All cells were detached, centrifuged, and resuspended in thrombin 
solution (Sigma-Aldrich) (4 U mL−1 in VascuLife) and left on ice. The 
tricellular suspension (20 µL) was mixed with fibrinogen (Sigma-Aldrich; 
20 µL, 6 mg mL−1 in DPBS) to achieve 6 × 106 cells mL−1 iPSC-ECs, 1 × 
106 cells mL−1 pericytes, and 1 × 106 cells mL−1 astrocytes. The mixture 
was injected into the gel filling port. Devices were placed upside-down 
in a humidified chamber and left for 15 min (RT) for gel polymerization. 
Then, “medium A,” EGM-2 + VEGF (Peprotech; 50 ng mL−1) + 1% (v/v) 
Astrocyte Growth Supplement (ScienCell), was introduced to both fluidic 
channels. “Medium B,” EGM-2 + 1% (v/v) AGS, was used from days 
5 to 7.
At day 2 or 3, medium was removed from one fluidic channel, 
replaced with fibronectin (30 µL, 60 µg mL−1 in DPBS) and left in the 
incubator for 30 min, before rinsing twice with DPBS. iPSC-ECs were 
detached, resuspended (2 × 106 cells mL−1 in medium A) and the 
suspension (30 µL) injected into the coated fluidic channel. Devices 
were tilted upside-down (60° angle) for 15 min (RT), allowing cells to 
spread evenly over the gel interface by gravity. Then, medium A was 
added to the fluidic channel. The following day, nonadherent iPSC-ECs 
were removed by replacing with fresh medium and the procedure 
performed for the other fluidic channel. Media was replaced daily 
(Figure 1).
3D Permeability Measurements and Quantification: All NPs were 
freshly prepared before each experiment and vortexed for 10 s before 
their use. A solution of 70 kDa FITC-dextran (Sigma-Aldrich) mixed with 
NPs was used for permeability experiments (100 µg mL−1 FITC-dextran 
and 50 µg mL−1 NPs in culture medium). Alternatively, a solution of 10, 
40, or 70 kDa FITC-dextran solution (100 µg mL−1 in culture medium) 
was used. NPs were red fluorescent with an optimal excitation and 
emission wavelength of 580 and 605 nm, respectively.
To measure the permeability of fluorescent NPs in 3D, medium 
was first removed from both fluidic channels of each device. In one 
fluidic channel, a solution containing NPs and FITC-dextran (15 µL) 
was added, while culture medium without NPs (15 µL) was added 
simultaneously in the other fluidic channel. In other experiments, 
solutions of FITC-dextrans with different molecular weights were 
used. 3D z-stacks of the microvasculature in the gel channel was 
imaged at 5 min intervals by confocal microscopy (512 × 512 pixels, 
20× magnification) (Olympus model FV1000) for at least three 
different ROI (of equal area and volume) that were taken along the 
length of the microfluidic channel to ensure non-biased sampling of 
the microvasculature (Figure 3a). Video recording of NP movement 
through the in vitro BBB microvasculature was obtained using NIS-
Elements software (Nikon) on a fluorescence microscope (Nikon, 
Ti-E Eclipse) (1392 × 1040 pixels, 20× magnification, 15 frames s−1) 
(Movie S1, Supporting Information).
NP permeability was quantified by considering the increase in 
fluorescence intensity of FITC-dextran and NPs within the gel using 
Equation (2)
( )
( )
−
∆ −
Permeability =
I I V
A t I I
g,t2 g,t1 g
v v,t1 g,t1  
(2)
where the subscripts g and v stand for the gel region and vascular region, 
respectively, I is the mean intensity of the signal within the ROI, Vg is 
the volume of the gel, Av is the lateral surface of the microvasculature, 
and ∆t = t2–t1 is the duration of the test (5 to 30 min). As described 
in Equation (2), the same volume of gel to volume of microvasculature 
is considered in the calculation of permeability for each ROI over two 
subsequent timepoints. Geometrical parameters such as lateral area and 
volume of the network were computed using Fiji software by segmenting 
the images using the FITC-dextran signal with the 3D Trainable Weka 
Segmentation plugin and an ad hoc classifier. The above-described 
measurements were derived based on the 3D analysis of the confocal 
image stacks of the microvasculature as previously described.[51]
Generation of 3D Intensity Map Showing Spatiotemporal Distribution: 
3D intensity maps were generated to assess the spatial distribution 
of NPs within the gel at each timepoint using 3D confocal image 
stacks. The fluorescence intensity of NPs in the ROI, which include the 
microvasculature and surrounding gel region, was then plotted in 3D. To 
achieve this aim, TIFF 3D stacks were converted to VTK files using a Matlab 
code (https://it.mathworks.com/matlabcentral/fileexchange/58819-write-
2d-and-3d-arrays-into-vtk), before displaying the final 3D intensity maps 
using Paraview (https://www.paraview.org/). Spatiotemporal distribution 
analysis was performed using Fiji software (http://rsbweb.nih.gov/ij/). 
Briefly, intensity images were sampled along specific lines drawn within 
single image planes across different timepoints. Then, intensity profile 
histograms of the cross-section were plotted.
Statistical Analysis: All data were plotted as the mean ± standard 
deviation (SD) using Prism (GraphPad software). Statistical analysis was 
determined using a two-tailed Student’s t-test and where appropriate, 
one-way ANOVA with Holm–Sidak’s multiple comparisons test or 
Kruskal–Wallis H test with Dunn’s multiple comparisons test. Bar 
graphs display the pooled results (mean ± SD) of ≥3 independent 
experiments (3–5 devices per condition for each experiment; ≥3 ROI 
for each device; total ROI per condition on average n = 30). p values 
and adjusted p values of less than 0.05 were taken as evidence of a 
statistically significant difference.
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